Stanford University
Showing 121-130 of 136 Results
-
Daniel SW Ting
Adjunct Clinical Associate Professor, Ophthalmology
BioDaniel Ting, MD, PhD, Stanford Adjunct Associate Professor and Duke-NUS Jong Soy Leong Professor, is one of the world's leading clinician-AI scientists, vitreoretinal surgeons, technology innovators and entrepreneurs, with expertise spanning retinal medicine and surgery, AI and healthcare technology. His work sits at the intersection of medicine, AI, innovation and technology translation. A former US-ASEAN Fulbright Scholar at the Johns Hopkins University Applied Physics Laboratory and School of Medicine, his research spans machine learning, deep learning, large language models, multimodal foundation models, explainable AI and privacy-preserving technologies, alongside safe, responsible and ethical clinical AI. He has contributed to international consensus and reporting initiatives including STARD-AI, QUADAS-AI and DECIDE-AI.
Professor Ting works across the full translational spectrum of AI in healthcare, from algorithm development and multimodal foundation models to generative and agentic AI, clinical implementation, regulatory science, health economics and commercialization. He is Founding Co-Director of the SingHealth Duke-NUS Artificial Intelligence in Medicine Institute (AIMI), Director of the SingHealth AI Office, Chief Data & Digital Officer of the Singapore National Eye Centre, and Head of AI & Digital Innovation at the Singapore Eye Research Institute. He serves on Singapore's Ministry of Health AI Steering Committee and is a core leader of SIMFONI, Singapore's national programme for sovereign multimodal foundation models in healthcare.
His research has advanced the development, validation and real-world deployment of medical AI, including national-scale AI-enabled diabetic retinopathy screening, health-economic evaluation, privacy-preserving AI, medical imaging foundation models and responsible generative AI. More recently, his work has expanded into sovereign agentic AI and enterprise AI orchestration, combining frontier models, specialised agents, institutional knowledge, verification and structured human oversight for regulated environments.
Professor Ting has authored more than 400 peer-reviewed publications, attracting more than 45,000 citations with an H-index above 86, including influential work in JAMA, The Lancet, Nature Medicine, Nature Biomedical Engineering, The Lancet Digital Health and NEJM AI. He was recognised in the World's Top 100 AI Power List (2024) alongside AI leaders including Jensen Huang, Fei-Fei Li and Yann LeCun. He has been named among Stanford University's World's Top 2% Scientists (2022–2026), the Top 100 Power List in Ophthalmology, and the World's Top 10 Ophthalmic Innovators (2025). Major honours include Singapore's Young Scientist Award, National Clinician Scientist Award, APAO Nakajima Award, APVRS Ian Constable Award, ARVO Bert Glaser Award and Macula Society Evangelos Gragoudas Award.
Professor Ting serves on the International Advisory Board of The Lancet Digital Health, is Section Editor for AI at the British Journal of Ophthalmology, and holds editorial leadership roles with Ophthalmology, Ophthalmology Retina and Ophthalmology Science. He also holds international leadership positions across the American Academy of Ophthalmology and major Asia-Pacific ophthalmology and vitreoretinal societies.
Beyond academia, Professor Ting is a serial inventor, start-up founder and technology entrepreneur, co-founding ventures spanning medical AI, ophthalmology, healthy longevity and sovereign agentic AI. His work bridges Stanford and Silicon Valley's frontier AI and innovation ecosystem with Singapore's integrated healthcare and national AI infrastructure, translating frontier AI into trusted and scalable technologies. His mission is to build the next generation of trusted, sovereign and clinically intelligent AI systems, moving healthcare AI from algorithms to infrastructure, from prediction to reasoning, and from scientific discovery to global-scale impact. -
Andreas Tolias
Professor of Ophthalmology
BioAndreas Tolias is a faculty member at Stanford University, where he co-leads the Enigma Project. His research lies at the interface of neuroscience and AI, combining large-scale neuroscience experiments with machine learning to uncover the principles of natural intelligence. By focusing on perceptual inference and decision-making, his lab integrates systems and computational neuroscience with AI to decipher the network-level principles of intelligence. Dr. Tolias’s work aims to reverse-engineer these principles to create AI systems that are smarter, more robust, trustworthy, and efficient, while providing a powerful platform to test brain algorithms under complex natural tasks. He earned his B.A. and M.A. in Natural Sciences from the University of Cambridge, a Ph.D. in Systems and Computational Neuroscience from MIT, and completed postdoctoral training in Neuroscience and Machine Learning at the Max Planck Institute for Biological Cybernetics in Tübingen.
-
Karen Wai, MD
Clinical Assistant Professor, Ophthalmology
BioDr. Wai is a board-certified ophthalmologist and fellowship-trained vitreoretinal surgeon with Stanford Health Care Byers Eye Institute. She is also a clinical assistant professor of ophthalmology in the Department of Ophthalmology at Stanford University School of Medicine.
Dr. Wai is a retina specialist who diagnoses and treats retinal and macular diseases, including age-related macular degeneration, diabetic retinopathy, retinal vascular occlusions (blockages), and retinal tears/detachments. The retina is a tissue layer in the back of the eye. It converts light into signals that the brain then interprets as images. The macula is the part of the retina responsible for central (straight ahead) vision. Diseases of the retina and macula can cause low vision and vision loss.
Dr. Wai’s research interests include working with data from electronic health record databases to improve patient outcomes. She has researched morbidity and mortality (illness and death) rates in patients with retinal vein occlusions and retinal artery occlusions. A retinal vein occlusion is a blocked vein to the retina that can cause vision loss. A retinal artery occlusion is when an artery to the retina is blocked, which is also sometimes referred to as eye stroke. Dr. Wai has also examined the effects of systemic medications on the retina. She has won several ophthalmology awards, including the Heed Fellowship and Harvard Medical School’s Excellence in Clinical Instruction Resident Award.
Dr. Wai has published in more than 40 peer-reviewed journals, including Ophthalmology, American Journal of Ophthalmology, and JAMA Ophthalmology. She has presented research at meetings and conferences around the United States.
Dr. Wai is a member of the American Board of Ophthalmology. -
Brian A. Wandell
Isaac and Madeline Stein Family Professor and Professor, by courtesy, of Electrical Engineering, of Ophthalmology and of Education
Current Research and Scholarly InterestsModels and measures of the human visual system. The brain pathways essential for reading development. Diffusion tensor imaging, functional magnetic resonance imaging and computational modeling of visual perception and brain processes. Image systems simulations of optics and sensors and image processing. Data and computation management for reproducible research.
-
Sean Ku Wang, MD
Clinical Instructor, Ophthalmology
BioDr. Sean Ku Wang is a board-certified ophthalmologist and fellowship-trained retina specialist with Stanford Health Care and an Assistant Professor of Ophthalmology at Stanford University.
Dr. Wang specializes in treating diseases of the retina and macula, including age-related macular degeneration, diabetic retinopathy, central serous chorioretinopathy, and retinal vascular occlusions. He is committed to providing individualized, high-quality care to achieve the best possible outcomes for his patients.
Dr. Wang’s research aims to accelerate the development of safe and effective genetic therapies. By integrating approaches from genetics, immunology, synthetic biology, computer science, and medicine, his lab seeks to discover and translate new treatments for human diseases with an emphasis on blinding disorders. His work has been published in leading scientific journals such as Nature, Nature Biotechnology, Journal of Clinical Investigation, and Proceedings of the National Academy of Sciences.
Dr. Wang has been recognized as a STAT Wunderkind, Forbes 30 Under 30, and a recipient of the American Society for Clinical Investigation Emerging-Generation Award and Burroughs Wellcome Fund Career Award for Medical Scientists among other honors. -
Sophia Y. Wang, MD, MS
Assistant Professor of Ophthalmology
Current Research and Scholarly InterestsI use and integrate a wide variety of data sources in my research, spanning both structured and unstructured forms, including national survey datasets, health insurance claims data, patient generated online text, surgical video, and electronic health records. I investigate outcomes of treatments for glaucoma and cataract, as well as other areas of ophthalmology. My focus is on developing artificial intelligence methods to predict ophthalmology outcomes, while ensuring fairness.
-
Sui Wang, PhD
Associate Professor of Ophthalmology
On Leave from 2026-09-15 To 2026-12-15Current Research and Scholarly InterestsOur research focuses on unraveling the molecular mechanisms underlying retinal development and diseases. We employ genetic and genomic tools to explore how various retinal cell types, including neurons, glia, and the vasculature, respond to developmental cues and disease insults at the epigenomic and transcriptional levels. In addition, we investigate their interactions and collective contributions to maintain retinal integrity.
1. Investigating retinal development:
We utilize genetic tools and methods such as in vivo plasmid electroporation and CRISPR to dissect the roles of cis-regulatory elements and transcription factors in controlling retinal development.
2. Understanding diabetes-induced cell-type-specific responses in the retina:
Diabetes triggers a range of multicellular responses in the retina, such as vascular lesions, glial dysfunction, and neurodegeneration, all of which contribute to retinopathy. We delve into the detailed molecular mechanisms underlying these diabetes-induced cell-type-specific responses and the pathogenesis of diabetic retinopathy.
3. Developing molecular tools for labeling and manipulation of specific cell types in vivo:
Cis-regulatory elements, particularly enhancers, play pivotal roles in directing tissue- and cell-type-specific expression. Our interest lies in identifying enhancers that can drive cell type-specific expression in the retina and brain. We incorporate these enhancers into plasmid or AAV-based delivery systems, enabling precise labeling and manipulation of specific cell types in vivo.
